HC Wainwright Reiterates Neutral Rating for Hookipa Pharma (NASDAQ:HOOK)

Hookipa Pharma (NASDAQ:HOOK)‘s stock had its “neutral” rating reiterated by equities research analysts at HC Wainwright in a research note issued to investors on Friday, MarketBeat Ratings reports.

Other equities research analysts have also issued reports about the stock. Royal Bank of Canada lowered shares of Hookipa Pharma from an “outperform” rating to a “sector perform” rating and decreased their target price for the company from $48.00 to $2.00 in a research note on Friday, December 20th. JMP Securities reduced their price objective on Hookipa Pharma from $24.00 to $7.00 and set a “market outperform” rating for the company in a research report on Thursday, November 21st.

Hookipa Pharma Stock Up 15.6 %

Shares of NASDAQ HOOK opened at $2.15 on Friday. The firm’s 50-day moving average price is $2.48 and its 200-day moving average price is $4.10. Hookipa Pharma has a 52-week low of $1.75 and a 52-week high of $10.50. The company has a market cap of $25.92 million, a PE ratio of -0.58 and a beta of 0.71.

Hedge Funds Weigh In On Hookipa Pharma

A number of institutional investors have recently bought and sold shares of HOOK. Renaissance Technologies LLC raised its stake in shares of Hookipa Pharma by 38.4% in the second quarter. Renaissance Technologies LLC now owns 302,246 shares of the company’s stock worth $179,000 after buying an additional 83,800 shares during the period. Ikarian Capital LLC purchased a new stake in Hookipa Pharma in the 3rd quarter worth approximately $228,000. Finally, Acadian Asset Management LLC raised its stake in Hookipa Pharma by 12.3% during the 2nd quarter. Acadian Asset Management LLC now owns 991,106 shares of the company’s stock worth $586,000 after acquiring an additional 108,844 shares during the period. 63.88% of the stock is owned by institutional investors.

Hookipa Pharma Company Profile

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.